Curetis

The new panel is able to detect up to 130 pathogens that cause severe abdominal infections, such as appendicitis and acute pancreatitis. 

The company attributed the decline in part to nonrecurring sales of its Unyvero molecular diagnostic system to partners for clinical trials and regulatory clearances.

Ares plans to use the GEAR database to discover new markers of antibiotic resistance and will eventually develop it as an interpretation service. 

Curetis' new subsidiary will focus on using a recently acquired database of bacterial genome sequences to identify novel antibiotic resistance markers. 

Curetis recently completed a clinical trial that compared the panel to both microbiology and individual PCR testing plus sequencing.

The firm plans to develop a line of tests on the system that could include panels for infection control, viral testing, CNS infections, and assays for immunocompromised patients.

The deal also includes milestone payments to Carpegen and Systec totaling €2.5M and a potential for €9M in royalty-based earnings.

For the 40-target panel, the trial found an overall average weighted sensitivity and specificity of 90 and 99 percent, respectively.

The company said the cartridge now covers 102 diagnostic targets including 85 pathogens and 17 treatment resistance markers.

The company also cut its net loss in the first half of the year to €6.7 million from €12.4 million in the year-ago period.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.